Contributions
Abstract: P679
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: Worldwide, incidence and prevalence of multiple sclerosis (MS) have increased over the last decades. We present a systematic epidemiological study with recent prevalence and incidence rates of MS in Bavaria.
Methods: Incidence and prevalence of MS stratified by gender, age groups and region were analyzed by data records from 2006 to 2015 of more than 10 million people insured by the Association of Statutory Health Insurance Physicians of Bavaria. Official statistics of the German Federal Ministry of Health provided the size of the general population. Future prevalence was estimated with a predictive model.
Results: From 2006 to 2015 prevalence of MS in Bavaria increased from 228 per 100,000 to 364 per 100,000, while incidence rates remained relatively stable (female to male ratio 2:1, median 23.02, range 21.00 to 23.92 per 100,000 inhabitants). Incidence and prevalence were higher in urban than urbanized and rural areas. The prevalence is expected to increase to 474 per 100,000 in 2040 with the highest prevalence rates between 55 and 70 years.
Conclusion: The prevalence of MS in Bavaria is among the highest worldwide and will further rise over the next two decades. This demonstrates a need to strengthen healthcare provision systems due to the increasing numbers of particularly older patients with MS in the future.
Keywords: multiple sclerosis, prevalence, incidence, regional distribution, Bavaria, Germany
Disclosure: Bernhard Hemmer has served on scientific advisory boards for F. Hoffmann-La Roche Ltd, Novartis, Bayer AG, and Genentech; he has served as DMSC member for AllergyCare and TG therapeutics; he or his institution have received speaker honoraria from Biogen Idec, Teva Neuroscience, Merck Serono, Medimmune, Novartis, Desitin, and F. Hoffmann-La Roche Ltd; his institution has received research support from Chugai Pharmaceuticals and Biogen; holds part of two patents; one for the detection of antibodies against KIR4.1 in a subpopulation of MS patients and one for genetic determinants of neutralizing antibodies to interferon β. Alexander Hapfelmeier: Received a honorarium from Biogen for consulting services for the Biogen Symposium on Statistical Methods in Real World Evidence 2017. Tanja Daltrozzo: nothing to disclose. Ewan Donnachie: nothing to disclose. Antonius Schneider: nothing to disclose.
BH is supported by the Bundesminsterium für Bildung und Forschung (Kompetenznetz Multiple Sklerose KKNMS) and the Deutsche Forschungsgemeinschaft DFG (TR 128). No sponsor had any influence on design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript and decision to submit the manuscript for publication
Abstract: P679
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: Worldwide, incidence and prevalence of multiple sclerosis (MS) have increased over the last decades. We present a systematic epidemiological study with recent prevalence and incidence rates of MS in Bavaria.
Methods: Incidence and prevalence of MS stratified by gender, age groups and region were analyzed by data records from 2006 to 2015 of more than 10 million people insured by the Association of Statutory Health Insurance Physicians of Bavaria. Official statistics of the German Federal Ministry of Health provided the size of the general population. Future prevalence was estimated with a predictive model.
Results: From 2006 to 2015 prevalence of MS in Bavaria increased from 228 per 100,000 to 364 per 100,000, while incidence rates remained relatively stable (female to male ratio 2:1, median 23.02, range 21.00 to 23.92 per 100,000 inhabitants). Incidence and prevalence were higher in urban than urbanized and rural areas. The prevalence is expected to increase to 474 per 100,000 in 2040 with the highest prevalence rates between 55 and 70 years.
Conclusion: The prevalence of MS in Bavaria is among the highest worldwide and will further rise over the next two decades. This demonstrates a need to strengthen healthcare provision systems due to the increasing numbers of particularly older patients with MS in the future.
Keywords: multiple sclerosis, prevalence, incidence, regional distribution, Bavaria, Germany
Disclosure: Bernhard Hemmer has served on scientific advisory boards for F. Hoffmann-La Roche Ltd, Novartis, Bayer AG, and Genentech; he has served as DMSC member for AllergyCare and TG therapeutics; he or his institution have received speaker honoraria from Biogen Idec, Teva Neuroscience, Merck Serono, Medimmune, Novartis, Desitin, and F. Hoffmann-La Roche Ltd; his institution has received research support from Chugai Pharmaceuticals and Biogen; holds part of two patents; one for the detection of antibodies against KIR4.1 in a subpopulation of MS patients and one for genetic determinants of neutralizing antibodies to interferon β. Alexander Hapfelmeier: Received a honorarium from Biogen for consulting services for the Biogen Symposium on Statistical Methods in Real World Evidence 2017. Tanja Daltrozzo: nothing to disclose. Ewan Donnachie: nothing to disclose. Antonius Schneider: nothing to disclose.
BH is supported by the Bundesminsterium für Bildung und Forschung (Kompetenznetz Multiple Sklerose KKNMS) and the Deutsche Forschungsgemeinschaft DFG (TR 128). No sponsor had any influence on design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript and decision to submit the manuscript for publication